Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elici...

Full description

Bibliographic Details
Main Authors:	Madan, Ravi A, Heery, Christopher R, Gulley, James L
Format:	Online
Language:	English
Published:	Landes Bioscience 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/

id	pubmed-4091323
recordtype	oai_dc
spelling	pubmed-40913232014-08-05 Poxviral-based vaccine elicits immunologic responses in prostate cancer patients Madan, Ravi A Heery, Christopher R Gulley, James L Author's View Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches. Landes Bioscience 2014-04-29 /pmc/articles/PMC4091323/ /pubmed/25097802 http://dx.doi.org/10.4161/onci.28611 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Madan, Ravi A Heery, Christopher R Gulley, James L
spellingShingle	Madan, Ravi A Heery, Christopher R Gulley, James L Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
author_facet	Madan, Ravi A Heery, Christopher R Gulley, James L
author_sort	Madan, Ravi A
title	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_short	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_full	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_fullStr	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_full_unstemmed	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_sort	poxviral-based vaccine elicits immunologic responses in prostate cancer patients
description	Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches.
publisher	Landes Bioscience
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/
_version_	1613111266292793344

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

Similar Items